Innovative Cellular Therapeutics Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $40M

  • Investors
  • 10

Innovative Cellular Therapeutics General Information

Description

Developer of chimeric antigen receptor T cells products designed to treat blood cancers and solid tumors. The company is developing cellular immunotherapies for the treatment of late-stage solid tumors, such as colorectal cancer and thyroid cancer, enabling patients to recover from cancer disease and live healthy life.

Contact Information

Website
www.ictbio.com
Formerly Known As
SiDanSai Biotechnology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 50 West Gude Drive
  • Suite 60
  • Rockville, MD 20850
  • United States
+1 (240)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 50 West Gude Drive
  • Suite 60
  • Rockville, MD 20850
  • United States
+1 (240)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Innovative Cellular Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 06-Sep-2021 $40M Completed Clinical Trials - Phase 1
4. Later Stage VC (Series B1) 01-Nov-2019 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series B) 11-May-2018 Completed Clinical Trials - Phase 1
2. Later Stage VC (Series A) 08-Oct-2016 Completed Clinical Trials - Phase 1
1. Later Stage VC 08-Feb-2015 Completed Clinical Trials - Phase 1
To view Innovative Cellular Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Innovative Cellular Therapeutics Patents

Innovative Cellular Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020086989-A1 Increase or maintaining t-cell subpopulations in adoptive t-cell therapy Inactive 25-Oct-2018
WO-2020047306-A1 Chimeric antigen receptor cells for treating solid tumor Inactive 30-Aug-2018
JP-2021510540-A Amplification of modified cells and their applications Pending 11-Jan-2018
CA-3088161-A1 Modified cell expansion and uses thereof Pending 11-Jan-2018
WO-2019140100-A1 Modified cell expansion and uses thereof Inactive 11-Jan-2018 C12N15/625
To view Innovative Cellular Therapeutics’s complete patent history, request access »

Innovative Cellular Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Innovative Cellular Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
i-Qu & Co Venture Capital Minority
Hyfinity Investments Growth/Expansion Minority
LH Ventures (China) PE/Buyout Minority
Dunhou Capital Venture Capital Minority
SB China Venture Capital Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Innovative Cellular Therapeutics FAQs

  • When was Innovative Cellular Therapeutics founded?

    Innovative Cellular Therapeutics was founded in 2009.

  • Where is Innovative Cellular Therapeutics headquartered?

    Innovative Cellular Therapeutics is headquartered in Rockville, MD.

  • What is the size of Innovative Cellular Therapeutics?

    Innovative Cellular Therapeutics has 14 total employees.

  • What industry is Innovative Cellular Therapeutics in?

    Innovative Cellular Therapeutics’s primary industry is Drug Discovery.

  • Is Innovative Cellular Therapeutics a private or public company?

    Innovative Cellular Therapeutics is a Private company.

  • What is Innovative Cellular Therapeutics’s current revenue?

    The current revenue for Innovative Cellular Therapeutics is .

  • How much funding has Innovative Cellular Therapeutics raised over time?

    Innovative Cellular Therapeutics has raised $68.3M.

  • Who are Innovative Cellular Therapeutics’s investors?

    i-Qu & Co, Hyfinity Investments, LH Ventures (China), Dunhou Capital, and SB China Venture Capital are 5 of 10 investors who have invested in Innovative Cellular Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process